** Shares of drug developer Cargo Therapeutics CRGX.O rise 21% to $4.60 premarket
** On Tuesday, co said it is reducing its workforce by about 90%
** CRGX appointed Anup Radhakrishnan as interim CEO to lead the co through a potential merger or acquisition
** As of December 31, 2024, co had about 167 full-time employees - SEC filing
** Co also said it is stopping its experimental cancer therapy, CRG-023, and allogeneic platform
** Earlier this year, co halted a mid-stage trial for cancer treatment
** CRGX has $368.1 million in cash, as of December 31, 2024
** CRGX fell 36.5% last year
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。